Antibiotice SA

Antibiotice SA maintains a conservative capital structure with a debt-to-equity ratio of 0.25, indicating a relatively low reliance on debt financing. The company's liquidity position is moderate, as reflected by a current ratio of 2.02, but its cash and equivalents are minimal at RON 15,740, and its free cash flow is negative at RON -42,537,630. This suggests that the company is currently investing heavily in capital expenditures, which totaled RON -131,357,630 in the latest period. Profitability metrics show a return on equity of 5.55% and a return on assets of 3.72%, which are below the industry median for pharmaceutical companies. The company's operating income of RON 71,033,280 and net income of RON 51,769,470 indicate a stable but modest performance. Gross profit of RON 422,867,400 suggests that the company is managing production costs effectively, but its ability to convert this into higher returns is constrained. The company's revenue is derived from a diversified set of therapeutic areas, including infectious diseases, dermatology, cardiovascular, digestive, and musculoskeletal treatments. However, the input data does not provide specific segment or geographic revenue breakdowns, so it is unclear whether the company has significant concentration in any particular region or product line. Looking ahead, the company's growth trajectory is not explicitly outlined in the input data, but its capital expenditures suggest ongoing investment in production capabilities. Analysts have set a uniform price target of RON 2.00, with the last actual EPS at RON 0.09, indicating a potential for modest earnings growth. However, the company's free cash flow remains negative, which could limit its ability to fund future expansion without external financing. The risk assessment highlights a medium liquidity risk, primarily due to the company's negative net cash position after accounting for total debt. While dilution risk is currently low, the company's capital structure and ongoing investments may expose it to future dilution if it needs to raise additional capital. No specific dilution sources are identified in the input data, but the company's capital expenditures and negative free cash flow suggest a potential need for financing. Recent events and filings are not detailed in the input data, but the company's ongoing R&D activities and production line certifications suggest a focus on maintaining and expanding its product portfolio. The company's engagement in research and development is a key strategic driver, though the financial impact of these activities is not quantified in the provided data.